Addition of Atezolizumab to Chemo May Not Increase Treatment Burden
The addition of atezolizumab to standard chemotherapy does not appear to increase the treatment burden in patients with extensive-stage small-cell lung cancer.
The addition of atezolizumab to standard chemotherapy does not appear to increase the treatment burden in patients with extensive-stage small-cell lung cancer.
Two approaches to downstaging muscle-invasive bladder cancer prior to radical cystectomy include neoadjuvant chemotherapy and transurethral resection.
Pegvorhyaluronidase alfa is an enzyme that breaks down hyaluronan, thought to be a contributor to the structure of the tumor microenvironment in some pancreatic cancers.
The FDA has granted Orphan Drug designation to avatrombopag for the potential treatment of chemotherapy-induced thrombocytopenia, a complication that may lead to chemotherapy dose delays and regimen changes.
Cardio-oncology is an emerging field focusing on the detection, monitoring, and treatment of cardiac dysfunction related to systemic or radiation therapy.
The addition of trastuzumab to adjuvant chemotherapy did not improve outcomes for patients with HER2-low invasive breast cancer, a phase 3 randomized trial showed.
In a randomized phase 3 trial, researchers sought to determine if cetuximab-based chemoradiotherapy could be a less-toxic alternative to cisplatin-based chemoradiotherapy in patients with HPV-positive oropharyngeal cancer.
Cinvanti injectable emulsion can be administered as a 2-minute intravenous injection or 30-minute intravenous infusion.
Measuring a tumor’s response to neoadjuvant chemotherapy can be prognostic, providing important clues about a patient’s likely outcome following treatment.
An evaluation of patient education materials on chemotherapy for breast cancer revealed that many do not meet NIH recommendations.